Vishal Sikri
President chez Inivata Ltd.
Fortune : 2 M $ au 30/04/2024
Profil
Vishal Sikri is currently the President & Chief Commercial Officer at Inivata Ltd.
He previously worked as the President-Advanced Diagnostics at NeoGenomics, Inc. from 2022 to 2024.
Mr. Sikri has an undergraduate degree from Beloit College, an MBA from Loyola University of Chicago, and a graduate degree from the University of Wisconsin.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NEOGENOMICS, INC.
0,10% | 25/03/2024 | 129 085 ( 0,10% ) | 2 M $ | 30/04/2024 |
Postes actifs de Vishal Sikri
| Sociétés | Poste | Début |
|---|---|---|
Inivata Ltd.
 Inivata Ltd. Packaged SoftwareTechnology Services Inivata Ltd. develops new clinical applications for ctDNA analysis. It is a clinical cancer genomics company harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment. The firm is focused on developing clinical applications of ctDNA through collaborations with clinical oncologists at prominent academic institutions, leading community treatment centres and innovative biopharmaceutical companies. The company was founded by James Brenton, Tim Forshew, Rosenfeld Nitzan and Davina Gale on July 23, 2014 and is headquartered in Cambridge, the United Kingdom. | President | 23/05/2022 |
Anciens postes connus de Vishal Sikri
| Sociétés | Poste | Fin |
|---|---|---|
| NEOGENOMICS, INC. | Corporate Officer/Principal | 15/04/2024 |
Formation de Vishal Sikri
| Beloit College | Undergraduate Degree |
| University of Wisconsin | Graduate Degree |
| Loyola University of Chicago | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NEOGENOMICS, INC. | Health Services |
| Entreprise privées | 1 |
|---|---|
Inivata Ltd.
Inivata Ltd. Packaged SoftwareTechnology Services Inivata Ltd. develops new clinical applications for ctDNA analysis. It is a clinical cancer genomics company harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment. The firm is focused on developing clinical applications of ctDNA through collaborations with clinical oncologists at prominent academic institutions, leading community treatment centres and innovative biopharmaceutical companies. The company was founded by James Brenton, Tim Forshew, Rosenfeld Nitzan and Davina Gale on July 23, 2014 and is headquartered in Cambridge, the United Kingdom. | Technology Services |
